Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Modified chitosan in this context refers to a medical-grade, chemically altered derivative of the natural polysaccharide chitosan, designed for intra-articular injection. It serves as a biomimetic synovial fluid (viscosupplement) for the treatment of knee osteoarthritis, particularly in patients with cartilage defects. By mimicking the rheological and lubricating properties of healthy synovial fluid, it aims to reduce joint friction, alleviate pain, and potentially provide a protective environment for articular cartilage. The modification of the chitosan backbone is typically performed to improve its solubility at physiological pH and to optimize its viscoelastic properties for joint lubrication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on modified chitosan.